Gastrointestinal Stromal Tumor (GIST)

01Pathophysiology

Gastrointestinal stromal tumors are the most common mesenchymal neoplasms of the gastrointestinal tract. They originate from the interstitial cells of Cajal (ICC) or their stem cell precursors. The ICC serve as the "pacemaker cells" of the gut, coordinating rhythmic peristaltic contractions by generating slow-wave electrical activity between the autonomic nervous system and smooth muscle layers. This origin explains why GISTs arise within the muscularis propria of the bowel wall, presenting as submucosal or subserosal masses rather than mucosal lesions.

The central molecular event in the majority of GISTs is a gain-of-function mutation in the KIT proto-oncogene (located on chromosome 4q12), which encodes a type III receptor tyrosine kinase known as CD117. Under normal conditions, the KIT receptor is activated only when bound by its ligand, stem cell factor (SCF). In GIST, the mutation causes constitutive, ligand-independent activation of the KIT receptor, leading to uncontrolled cell proliferation, resistance to apoptosis, and tumor growth. Approximately 5 to 10% of GISTs instead harbor a mutation in the platelet-derived growth factor receptor alpha (PDGFRA) gene, which is a closely related tyrosine kinase that drives tumorigenesis through a parallel signaling cascade. A small subset (~10 to 15%) are KIT/PDGFRA wild-type and may involve alternative pathways such as SDH deficiency, BRAF mutations, or NTRK fusions.

The stomach is the most common site of origin (~60%), followed by the small intestine (~25 to 30%), colon, rectum, and rarely the esophagus or omentum. Because GISTs grow outward (exophytically) from the muscularis propria, they often reach a considerable size before causing symptoms. Mucosal ulceration overlying the tumor explains the classic presentation of GI bleeding. The submucosal growth pattern also explains why standard mucosal biopsies during routine endoscopy frequently return non-diagnostic tissue, necessitating deeper sampling techniques like endoscopic ultrasound-guided fine needle aspiration (EUS-FNA).

GISTs metastasize most commonly to the liver and peritoneum. Lymph node metastasis is exceedingly rare, which is a key distinguishing feature from GI carcinomas and lymphomas. This is why lymph node dissection is not part of the standard surgical approach.

02Classification and Clinical Manifestation

GISTs are risk-stratified based on three parameters: tumor size, mitotic rate, and anatomic location. The most widely used system is the modified NIH (National Institutes of Health) classification, sometimes referred to as the Miettinen-Lasota criteria, derived from Armed Forces Institute of Pathology (AFIP) data.

Anatomic location modifies risk: small intestinal GISTs carry a worse prognosis than gastric GISTs of the same size and mitotic rate. Rectal GISTs also tend toward more aggressive behavior.

Clinical manifestations depend on tumor size and location:

03Diagnostic Workup

The best initial test when a GI mass is suspected on clinical grounds is contrast-enhanced CT of the abdomen and pelvis. CT will demonstrate the characteristic well-defined, often large, hypervascular mass with an exophytic growth pattern originating from the stomach or small bowel wall. Look for heterogeneous enhancement or central low attenuation in larger tumors, which indicates internal hemorrhage or necrosis.

If a submucosal mass is encountered during endoscopy, the next step is endoscopic ultrasound (EUS), which is critical for two reasons: it identifies the layer of origin (muscularis propria, the 4th layer, is characteristic of GIST), and it allows tissue sampling through FNA or fine needle biopsy (FNB). Standard endoscopic mucosal biopsies are usually non-diagnostic because the tumor sits beneath the mucosa.

The most accurate (confirmatory) test is histopathological examination with immunohistochemistry (IHC). The hallmark is a spindle cell proliferation that stains positive for CD117 (c-KIT) and DOG1. DOG1 is particularly valuable because it is positive in the ~5% of GISTs that are CD117-negative. Key negative markers include desmin (positive in leiomyomas/leiomyosarcomas), S-100 (positive in schwannomas), and CD34 (positive in many GISTs but non-discriminatory since other tumors also express it).

Mutational analysis is not used for initial diagnosis but is essential before starting targeted therapy. The exon location of the KIT mutation predicts response to imatinib: KIT exon 11 mutations (most common, ~65 to 70%) have the best response to imatinib, while KIT exon 9 mutations require a higher dose (800 mg daily vs. 400 mg). The PDGFRA D842V mutation is notably resistant to imatinib but sensitive to avapritinib.

Important: percutaneous biopsy of a resectable GIST is generally avoided due to the risk of tumor rupture, hemorrhage, and peritoneal seeding. Biopsy is reserved for cases where neoadjuvant therapy is being considered or when the diagnosis is uncertain and the mass is not straightforwardly resectable.

04Management and Treatment

Surgical resection is the cornerstone of curative treatment for localized GIST. The operation aims for negative microscopic margins (R0) with an intact tumor pseudocapsule. Unlike carcinomas, GISTs rarely metastasize to lymph nodes, so formal lymphadenectomy is not performed. The single most important intraoperative principle is to avoid tumor rupture, as rupture is considered equivalent to peritoneal dissemination and upgrades the tumor to high-risk regardless of size or mitotic count.

Imatinib mesylate is the landmark targeted therapy for GIST. It works by competitively inhibiting the ATP-binding site of the KIT and PDGFRA receptor tyrosine kinases, thereby shutting down the constitutively active signaling cascade. In the adjuvant setting (after complete resection of high-risk tumors), 3 years of imatinib at 400 mg daily is the standard of care, based on trial data showing superior recurrence-free survival and overall survival compared to 1 year of therapy. In metastatic disease, imatinib is continued indefinitely because discontinuation is associated with rapid disease progression.

For imatinib failure (defined as disease progression or intolerance), the second-line agent is sunitinib, a multi-target tyrosine kinase inhibitor that also inhibits VEGFR, contributing an anti-angiogenic effect. Third-line therapy is regorafenib, another oral multikinase inhibitor. Avapritinib is reserved for GISTs harboring the PDGFRA D842V mutation, which is inherently resistant to imatinib, sunitinib, and regorafenib.

Contraindications and cautions: Imatinib has notable drug interactions through CYP3A4 metabolism. It can cause fluid retention, periorbital edema, diarrhea, and muscle cramps. Sunitinib carries risks of hand-foot syndrome, hypertension, and cardiotoxicity. These side effects are commonly tested in pharmacology-focused questions.

For very small (less than 2 cm), incidentally discovered, asymptomatic GISTs without high-risk features on EUS (irregular borders, cystic spaces, ulceration, echogenic foci, or high mitotic index), observation with periodic EUS surveillance is an acceptable approach.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on GIST questions is by confusing it with other spindle cell tumors of the GI tract, particularly leiomyoma and leiomyosarcoma. The vignette will describe a submucosal mass in the stomach with spindle cells on biopsy, and the answer hinges entirely on the immunohistochemistry panel. Remember: CD117 (c-KIT) and DOG1 positive equals GIST; desmin positive equals smooth muscle tumor (leiomyoma/leiomyosarcoma); S-100 positive equals schwannoma. This IHC distinction is the single most tested concept for this diagnosis.

A second common trap involves management sequencing. When a vignette presents a clearly resectable GIST, the answer is surgery first, not imatinib. Imatinib in the upfront setting is reserved for borderline resectable or unresectable cases (neoadjuvant intent) or for adjuvant therapy after resection of high-risk tumors. Students sometimes reflexively choose imatinib because they associate it strongly with GIST, but the question is testing whether you know that surgery remains the primary curative modality.

Third, watch for the PDGFRA D842V mutation distractor. If a question describes a GIST that fails to respond to imatinib and the mutational analysis reveals this variant, the answer is avapritinib, not dose escalation of imatinib or switching to sunitinib. This mutation is an important exception to the standard treatment algorithm.

Finally, remember that tumor rupture (whether spontaneous or iatrogenic during surgery) is treated as a high-risk event regardless of tumor size and mandates adjuvant imatinib. A vignette describing intraoperative capsule breach followed by a question about adjuvant therapy is testing this principle. The core competency across all GIST questions is the ability to integrate histopathologic data (cell morphology plus IHC markers) with molecular genetics (mutation type) to select the correct diagnostic conclusion and treatment pathway.